BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 22578156)

  • 1. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
    Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
    BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
    Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
    BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.
    Moschini M; Suardi N; Pellucchi F; Rocchini L; La Croce G; Capitanio U; Briganti A; Damiano R; Montorsi F; Colombo R
    Anticancer Res; 2014 Jun; 34(6):3225-30. PubMed ID: 24922698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
    Rink M; Lee DJ; Kent M; Xylinas E; Fritsche HM; Babjuk M; Brisuda A; Hansen J; Green DA; Aziz A; Cha EK; Novara G; Chun FK; Lotan Y; Bastian PJ; Tilki D; Gontero P; Pycha A; Baniel J; Mano R; Ficarra V; Trinh QD; Tagawa ST; Karakiewicz PI; Scherr DS; Sjoberg DD; Shariat SF;
    BJU Int; 2013 Mar; 111(3 Pt B):E30-6. PubMed ID: 22938654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.
    Gondo T; Nakashima J; Ohno Y; Choichiro O; Horiguchi Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Urology; 2012 May; 79(5):1085-91. PubMed ID: 22446338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy.
    Sejima T; Morizane S; Yao A; Isoyama T; Saito M; Amisaki T; Koumi T; Takenaka A
    Int J Urol; 2014 Jan; 21(1):52-7. PubMed ID: 23711293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy.
    Bruins HM; Wopat R; Mitra AP; Cai J; Miranda G; Skinner EC; Daneshmand S
    BJU Int; 2013 Mar; 111(3 Pt B):E37-42. PubMed ID: 22974410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer.
    Eisenberg MS; Boorjian SA; Cheville JC; Thompson RH; Thapa P; Kaushik D; Frank I
    J Urol; 2013 Dec; 190(6):2005-10. PubMed ID: 23770147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.
    Mitra AP; Quinn DI; Dorff TB; Skinner EC; Schuckman AK; Miranda G; Gill IS; Daneshmand S
    BJU Int; 2012 Mar; 109(6):846-54. PubMed ID: 21812902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome.
    Jokisch JF; Grimm T; Buchner A; Kretschmer A; Weinhold P; Stief CG; Karl A; Schulz GB
    Urol Int; 2020; 104(1-2):36-41. PubMed ID: 31242481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does patient age affect survival after radical cystectomy?
    Horovitz D; Turker P; Bostrom PJ; Mirtti T; Nurmi M; Kuk C; Kulkarni G; Fleshner NE; Finelli A; Jewett MA; Zlotta AR
    BJU Int; 2012 Dec; 110(11 Pt B):E486-93. PubMed ID: 22551360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Bolenz C; Gilfrich C; Otto W; Trojan L; Herrmann E; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    J Urol; 2012 Apr; 187(4):1210-4. PubMed ID: 22335861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A; English S; Kauffman EC; Din R; Khan A; Syed JR; Sztorc J; Mehedint D; Sharif M; Shi Y; Wilding G; Guru KA
    BJU Int; 2014 Aug; 114(2):253-60. PubMed ID: 24119175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
    Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
    J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.